Clinical trials: in Oman
Prevent Bleeding in Major Surgery
Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery
Proportion of surgeries in which the primary endpoint (overall assessment) is classified as success.
- Trial name
- WONDERS (NCT01365546)
- Testing
- human VWF/FVIII concentrate
- Where
- 15 sites in United States, Bulgaria and 7 more
- Volunteers
- 30 people
- Sponsor
- Octapharma
Congenital Bleeding Disorder, Haemophilia A
Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors
This trial is conducted in Africa and Asia. The aim of this study is to evaluate the efficacy of home treatment of joint bleeds (haemarthrosis) with NovoSeven® (activated recombinant human factor VII) in patients with haemophilia…
- Conditions
- Congenital Bleeding Disorder, Haemophilia A, Haemophilia B
- Trial name
- NCT01234545
- Testing
- activated recombinant human factor VII
- Where
- 5 sites in Algeria, Morocco and 3 more
- Volunteers
- 35 people
- Sponsor
- Novo Nordisk A/S
Acute Heart Failure
Gulf Acute Heart Failure Registry
The Gulf Heart Association (GHA) sponsored Gulf acute heart failure registry (Gulf CARE)is a multinational , multicentre, prospective, observational, hospital-based registry of patients with acute heart failure(AHF) with 3 month…
- Trial name
- GulfCARE (NCT01467973)
- Where
- Oman
- Volunteers
- 5,005 people
- Sponsor
- Gulf Heart Association
Hemophilia A
EFFEKT - Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FS
The aim of this international prospective, non-interventional post-marketing surveillance study is to obtain data on treatment procedures, long-term safety and efficacy and patient acceptance of KOGENATE Bayer in treatment of…
- Trial name
- NCT00874926
- Testing
- Recombinant Factor VIII (Kogenate FS, BAY14-2222)
- Where
- 17 sites in Bahrain, Bosnia and Herzegovina and 15 more
- Volunteers
- 405 people
- Sponsor
- Bayer
Transfusional Iron Overload
Active Drug Surveillance Program of Ferriprox Use
Observational, open label, prospective, multi-center, post-marketing drug surveillance program.
- Trial name
- NCT01838291
- Where
- 14 sites in Cyprus, Egypt and 3 more
- Volunteers
- 294 people
- Sponsor
- ApoPharma
Hypertension
Treatment of Hypertension With Adalat® in Combination With Other Drugs
To investigate the therapeutic effectiveness of long acting nifedipine containing combination therapy in the treatment of hypertensive patients.
- Trial name
- NCT01118286
- Testing
- Nifedipine (Adalat, BAYA1040)
- Where
- 11 sites in Bahrain, Egypt and 9 more
- Volunteers
- 4,497 people
- Sponsor
- Bayer
Multiple Sclerosis
Physical Activity and Fatigue in Early Multiple Sclerosis (MS)
The purpose of this observational study is to obtain a survey on physical activity in patients who for the first time have experienced symptoms which indicate a high risk for developing multiple sclerosis (MS) and in patients…
- Trial name
- BEGIN (NCT00882453)
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 33 sites in Australia, Austria and 31 more
- Volunteers
- 1,739 people
- Sponsor
- Bayer
Contraception
Effects of Counseling on the Continuation Rates and Compliance for Newly Prescribed Oral Contraceptives (Yasmin® or Any Other Oral Contraceptives (OC)
This study is a prospective, company-sponsored, non-interventional cohort study of up to 5000 patients in European countries and countries in Middle East who are newly prescribed any available OC.
- Trial name
- NCT00905684
- Testing
- EE30/DRSP (Yasmin, BAY86-5131), Any other OC
- Where
- 13 sites in Albania, Bahrain and 11 more
- Volunteers
- 5,446 people
- Sponsor
- Bayer
Beta-thalassemia Major, Hemosiderosis
Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)
To allow patients treated with deferasirox in the core study to continue iron chelation therapy for 2 years or until the drug became locally commercially available.
- Conditions
- Beta-thalassemia Major, Hemosiderosis, Iron Overload, Rare Anemia
- Trial name
- ESCALATOR (NCT00171301)
- Testing
- Deferasirox
- Where
- 5 sites in Egypt, Lebanon and 3 more
- Volunteers
- 233 people
- Sponsor
- Novartis Pharmaceuticals
Bipolar Disorder
Gulf Evaluation of VAlproate (Depakine Chrono) in maNia Study
To assess the efficacy of Di-valproate in Bipolar I patients suffering from a manic episode according to DSM IV (APA 1994) over a 12 weeks period of treatment. To evaluate the clinical safety of Di-valproate.
- Trial name
- GEVANS (NCT00477373)
- Testing
- depakine chrono
- Where
- 4 sites in Bahrain, Kuwait and 2 more
- Volunteers
- 70 people
- Sponsor
- Sanofi